NewGenIvf Group Limited Class A (NIVF) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of NewGenIvf Group Limited Class A $0.51, price $0.29, upside +74.9%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
55‑month range $0.1954 – $1,000,000 · fair‑value band $0.3812 – $0.7472 · the $0.2935 price screens below the $0.5132 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow NewGenIvf Group Limited Class A Ordinary Shares in your weekly email
Every Wednesday you see whether NewGenIvf Group Limited Class A Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan.
Show moreShow less
The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing.
It also offers IVF treatment; surrogacy and ancillary caring services, and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company provides its services through clinics.
NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
Stock analysis
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) currently trades at $0.2935, while our model-based Fair Value estimate is $0.5132, implying the stock looks roughly 42.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.3218 per share, and 2 of the 8 models we run sit above the $0.2935 price.
Bear case: the Economic Profit group reads lowest at $0.1121, and 6 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: $0.3812 (bear) to $0.7472 (bull), the price of $0.2935 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
NewGenIvf Group Limited Class A Ordinary Shares reported revenue of $4.7M in FY2025 versus $4.1M in FY2021, a compound +3.5%/yr. Reported net income was $9.9M in FY2025.
Key figures
Market cap $360K · P/E ratio 0.0 · EPS (TTM) $328.32 · Net margin 209% · Return on equity 79.4% · Return on assets (EBIT) −16.1% · Operating margin −349% · Revenue (TTM) $4.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 72 out of 100 (medium confidence).
What moves the price
The share trades about 100% below its 52-week high and 50% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 20% fair-value upside, at 75%, NIVF screens cheaper than that median.
Fair Value models
Bear$0.3812Fair Value $0.5132Bull$0.7472
Price $0.2935 · Upside +74.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($259.06 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.4%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.8% (2021) → −226.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
Compare NewGenIvf Group Limited Class A Ordinary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 6/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+74.9% · Top 25%
Profitability
Return on equity (12 months)79.4% · Top 25%
Return on assets30.2% · Top 25%
Growth and dividend
Revenue growth11.9% · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NewGenIvf Group Limited Class A Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/NIVF
Frequently asked questions
Is NewGenIvf Group Limited Class A (NIVF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.5132 versus a price of $0.2935, about +75% upside (undervalued).
What is the fair value of NIVF?
Our model-based fair value for NewGenIvf Group Limited Class A Ordinary Shares is $0.5132 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.2935.
What is the quality score of NIVF?
NewGenIvf Group Limited Class A Ordinary Shares has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NewGenIvf Group Limited Class A (NIVF)?
Our model-based price target is the fair value of $0.5132 (as of Oct 3, 2026) from 8 valuation models. Cautious scenario $0.3812, optimistic scenario $0.7472. It is a calculation from audited fundamentals, not an analyst target.
What is the NewGenIvf Group Limited Class A Ordinary Shares stock forecast for 2026?
Our models put fair value at $0.5132, about +75% upside versus a price of $0.2935 (undervalued). Cautious scenario $0.3812, optimistic scenario $0.7472. The calculation is refreshed regularly with new filings.
What is the revenue of NewGenIvf Group Limited Class A (NIVF)?
NewGenIvf Group Limited Class A Ordinary Shares reported trailing-twelve-month revenue of about $4.7M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of NewGenIvf Group Limited Class A (NIVF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NewGenIvf Group Limited Class A Ordinary Shares it is $0.5132 per share (as of Oct 3, 2026), against a price of $0.2935. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is NewGenIvf Group Limited Class A Ordinary Shares stock overvalued or undervalued in 2026?
As of Oct 3, 2026, NIVF trades below its calculated fair value: price $0.2935, fair value $0.5132, a gap of about +75% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NIVF?
No. The price is what the market pays today ($0.2935); the fair value is what the company's own numbers justify ($0.5132). For NewGenIvf Group Limited Class A Ordinary Shares the two are $0.2197 per share apart. That gap is exactly why we show both numbers side by side.
How much is NewGenIvf Group Limited Class A Ordinary Shares worth?
The market values NewGenIvf Group Limited Class A Ordinary Shares at about $360K (market capitalisation, as of Oct 3, 2026). Per share that is $0.2935; our models calculate a fair value of $0.5132 per share.
What do the bullish and bearish scenarios say about NIVF?
Our models span a range for NewGenIvf Group Limited Class A Ordinary Shares: cautious scenario $0.3812, base $0.5132, optimistic $0.7472 per share (as of Oct 3, 2026, price $0.2935). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NIVF?
NewGenIvf Group Limited Class A Ordinary Shares trades at a price-to-earnings ratio of 0.0 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.5132 is built from several models across several years. Other multiples: P/S 0.1.
How solid is the balance sheet of NewGenIvf Group Limited Class A (NIVF)?
Balance-sheet figures for NewGenIvf Group Limited Class A Ordinary Shares (as of Oct 3, 2026): return on equity 79.4%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is NIVF from its 52-week high?
NewGenIvf Group Limited Class A Ordinary Shares trades at $0.2935, about 100% below its 52-week high of $4,374 and 50% above the low of $0.1954 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5132 is for.
Which stocks are comparable to NewGenIvf Group Limited Class A Ordinary Shares?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NewGenIvf Group Limited Class A Ordinary Shares stock attractive at the current price?
The data as of Oct 3, 2026: price $0.2935, calculated fair value $0.5132 (+75%), Quality Score 35/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NIVF calculated?
We run NewGenIvf Group Limited Class A Ordinary Shares through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5132, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. NewGenIvf Group Limited Class A Ordinary Shares currently trades 43 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NewGenIvf Group Limited Class A (NIVF)?
The closing price on Oct 14, 2026 was $0.2935. Our model-based fair value is $0.5132, about +75% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NewGenIvf Group Limited Class A Ordinary Shares right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.3812). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3812 to $0.7472) leaves room in how you read the outcome.
Key figures of NewGenIvf Group Limited Class A Ordinary Shares
How large is the market capitalisation of NewGenIvf Group Limited Class A (NIVF)?
The market capitalisation of NewGenIvf Group Limited Class A Ordinary Shares is $360K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of NewGenIvf Group Limited Class A (NIVF)?
Earnings per share at NewGenIvf Group Limited Class A Ordinary Shares are $328.32 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NewGenIvf Group Limited Class A (NIVF)?
The net margin of NewGenIvf Group Limited Class A Ordinary Shares is 209% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NewGenIvf Group Limited Class A (NIVF)?
The return on equity (ROE) of NewGenIvf Group Limited Class A Ordinary Shares is 79.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NewGenIvf Group Limited Class A (NIVF)?
On an EBIT basis the return on assets of NewGenIvf Group Limited Class A Ordinary Shares is −16.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NewGenIvf Group Limited Class A (NIVF)?
The operating margin of NewGenIvf Group Limited Class A Ordinary Shares is −349% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NewGenIvf Group Limited Class A (NIVF)?
Revenue at NewGenIvf Group Limited Class A Ordinary Shares is growing +11.9% versus a year earlier (3y avg −7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NewGenIvf Group Limited Class A (NIVF) generate?
The free cash flow of NewGenIvf Group Limited Class A Ordinary Shares is −$16.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NewGenIvf Group Limited Class A (NIVF) carry?
The net debt of NewGenIvf Group Limited Class A Ordinary Shares is $4.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NewGenIvf Group Limited Class A Ordinary Shares in the live analysis
One click puts NewGenIvf Group Limited Class A Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 3, 2026